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and Vinit B Mahajan1,2*Abstract
Background: The purpose of this project was to identify short hairpin RNA (shRNA) sequences that can suppress
expression of human CAPN5 in which gain-of-function mutants cause autosomal dominant neovascular inflammatory
vitreoretinopathy (ADNIV). We created HEK293T cells that stably express an ADNIV disease allele, CAPN5-p.R243L.
Transfection protocols were optimized for neuroblastoma SHSY5Y cells. The gene silencing effect of four different
shRNA plasmids that target CAPN5 was tested. RNA and protein expression was determined using quantitative
RT-PCR and immunoblot analysis.
Findings: Two of four shRNA plasmids reduced mutant CAPN5 RNA in a stable cell line. Similar knockdown
was observed in SH-SY5Y cells that natively express CAPN5. Lactose dehydrogenase assays showed that
down-regulation of CAPN5 was not cytotoxic.
Conclusions: CAPN5 expression can be suppressed by shRNA-based RNA interference. Further testing in ADNIV models
will determine the potential of gene silencing as a strategy to treat, delay, or prevent blindness in ADNIV patients.
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CAPN5 mutations are the cause of Autosomal Dominant
Neovascular Inflammatory Vitreoretinopathy (ADNIV,
OMIM #602537), an inherited autoinflammatory uveitis
and vitreoretinal degeneration without systemic features
[1]. ADNIV patients are normally sighted until their
second decade when a chronic uveitis begins and cata-
racts develop. Over the next five decades, photoreceptor
degeneration, retinal neovascularization and intraocular
fibrosis occur sequentially and end in phthisis and
blindness [1,2].
CAPN5 encodes calpain-5, a calcium-activated cysteine
protease [3]. A single allele containing a nonsynonymous
mutation (CAPN5-p.R243L) is sufficient to cause ADNIV
[2,4,5]. The mutation is located within a gatekeeper do-
main that controls access to the active site [1]. The
CAPN5-p.R243L mutant allele is predicted to disrupt the* Correspondence: mahajanlab@gmail.com
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unless otherwise stated.gatekeeper domain and increase the calpain-5 proteolytic
activity. This gain of function model is consistent with the
mode of inheritance, high penetrance, disease severity,
and recent allele testing in a mouse model [6]. Therapies
that target secondary downstream effects are insufficient
to reverse disease [5], so therapies aimed at the primary
genetic defect are necessary.
Gene therapy for retinal diseases is feasible. Gene
replacement therapy was successfully applied in humans
for the autosomal recessive retinal degeneration associ-
ated with RPE65 Leber’s Congenital Amaurosis [7,8].
Gene silencing therapy, however, is required to treat
autosomal dominant gain of function diseases such as
ADNIV. Suppression of gene expression may be suffi-
cient to limit the CAPN5 disease allele physiological
activity and delay disease onset and progression. RNA-
based gene silencing is one approach that has been ap-
plied to mouse and cell models of similar dominantly
inherited retinal degenerations [9,10]. RNA-based gene
silencing has also been applied in cases of cytomegalo-
virus retinitis in patients with AIDS and in age-related
macular degeneration [11], supporting this general strat-
egy for human retinal therapy.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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specific complementary RNA sequences that form double
stranded RNA within cells. Short hairpin RNAs (shRNAs),
for example, are composed of a sense and antisense se-
quence connected by a loop of unpaired nucleotides [12].
shRNA binds to a target sequence, an RNase engaging
DICER cleaves the shRNA into siRNA, and the Argonaute
(AGO) protein cleaves the siRNA target sequence. A ma-
ture RNA-induced silencing complex (RISC) that contains
a guide strand and an AGO protein directs the complex
to associate with the target mRNA for degradation or
post-transcriptional gene silencing [12,13]. The purpose of
this study was to develop a disease-allele cell line, identify
shRNA sequences that reduce calpain-5 expression, and
deliver these to cells that natively express CAPN5.
Findings
CAPN5 stable cell line
To study the CAPN5-p.R243L disease allele in cultured
cells, we generated a stably expressing cell line using
HEK293T cells, which do not normally express calpain-
5. Immunoblot analyses of twenty-two cell colonies
revealed that seven of them successfully expressed the
mutant CAPN5 (Figure 1). A moderate expression col-
ony (lane 16) was selected for further experimentation.
After several passages, immunoblot verified that this line
continuously expressed CAPN5-p.R243L.
Transfection optimization
Four shRNA sequences targeting different human CAPN5
exons were selected for testing (Figure 2). HEK293-R243L
cells were transfected with the shRNA plasmids using a
lipid reagent and showed over 90% transfection efficiency
(Figure 3) and good cell viability (data not shown). Cells
expressing GFP were observed after 48 hours incubation
(Figure 3). In contrast to HEK293T cells, the human
neuroblastoma cell line SH-SY5Y expresses nativeFigure 1 Calpain-5 is stably expressed in HEK293T cells. HEK293T cells
twenty-two clones were analyzed. Calpain-5 protein expression was detect
GAPDH levels are indicated (lower panels). A HEK293T cell line that showed
silencing experiments.CAPN5 and has been used to study CAPN5 protein ex-
pression [14]. The transfection efficiencies of SH-SY5Y
cells using lipid-based reagents were less than 10% (data
not shown). Using electroporation, we optimized trans-
fection efficiencies in SH-SY5Y cells. The optimal elec-
troporation parameter for transfecting SH-SY5Y cells
was 1200 pulse voltage, 20 pulse width and 2 pulses.
This gave efficiencies up to 80% in SH-SY5Y (Figure 3).
GFP expressing SH-SY5Y cells were observed after
72 hours incubation. Cytotoxicity of the shRNA plas-
mids treatment was measured using an LDH assay. In
all the three cell lines, cytotoxicity of the shRNA clones
was minimal (Figure 3I).
Gene silencing
To determine which shRNA sequences would diminish
CAPN5-p.R243L expression, we tested 4 different hu-
man sequences and a nontargeting control sequence in
HEK293T-R243L cells. The nontargeting control se-
quence did not show significant suppression of the
CAPN5-p.R243L mRNA. Plasmid clones 1 and 2, which
targeted exons 13 and 9 of the mRNA respectively (Fig-
ure 4A), did not significantly suppress CAPN5 mRNA
levels. On the other hand, shRNA clones 3 and 4, which
targeted exons 6 and 8 of CAPN5 mRNA respectively,
were able to suppress CAPN5-p.R243L by over 70% and
50%, respectively (Figure 4A).
Next, we performed immunoblots to measure calpain-
5 protein levels. Clones 3 and 4 significantly reduced
calpain-5 expression levels in the HEK293T-R243L cell
line (Figures 4B and C). Knockdown was most pro-
nounced with clone 3 plasmid, showing over 70% de-
crease in both RNA and protein levels, compared to the
effect of the negative control.
To determine if these shRNA clones would suppress
native CAPN5, clones 3 and 4 were used to transfect the
human neuroblastoma cell line SH-SY5Y. Again, thewere co-transfected with CAPN5-p.R243L and puromycin plasmids and
ed with an anti-myc antibody in protein extracts (upper panels).
moderate expression (lane 16) was propagated for use in the
Figure 2 shRNA sequence targeting map. A. Schematic of the human CAPN5 gene and the alignment of four candidate anti-human CAPN5
shRNAs. The CAPN5 is composed of twelve exons that code for the four domains of calpain-5.
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mRNA levels, but clones 3 and 4 each reduced expres-
sion by approximately 65% (Figure 4D). Immunoblot
densities showed that both clones reduced calpain-5 by
approximately 70% (Figures 4E and F).
Discussion
In this study, we identified two shRNA sequences that ef-
fectively down-regulate both mutant and native CAPN5 at
the RNA and protein level. The disease allele of CAPN5 in
ADNIV represents a gain-of-function where there isFigure 3 Cells express GFP after transfection with plasmids. We tested
CAPN5-p.R243L (A-D) and SH-SY5Y (E-H). C, G. HEK293T-CAPN5-p.R243L and
control shRNA plasmid expressed GFP marker. In G. arrows show short neu
background labeling under fluorescent light. B, D. Under bright field, HEK2
cells proliferate as an adherent clump. Cells were visualized under 20X mag
knockdown of CAPN5 was not cytotoxic.enzymatic over-activity [1]. These data establish
shRNA-mediated RNA interference (RNAi) as a poten-
tial therapeutic strategy to rescue mutant CAPN5 dis-
ease phenotypes.
RNA interference using shRNA has been successful in
animal models of dominantly inherited ocular diseases
such as cone-rod dystrophy (retinitis pigmentosa) and
age-related macular degeneration [15,16]. RNA-based
gene silencing was also applied to the calpain-5 homolog
tra-3 in the C. elegans. RNA inhibition of tra-3 rescued
neurons from necrotic cell death [17]. Since necrotic cellthe transfection of shRNA-GFP plasmid in two cell types, HEK293T-
SH-SY5Y neuroblastoma cells successfully transfected with negative
ritis extend from cell. A, E. Cells not transfected with plasmid show no
93T-CAPN5-p.R243L cells proliferate as an adherent layer. F, H. SH-SY5Y
nification. Scale bars: 100 μm. I. As revealed by LDH assay, the
Figure 4 shRNA suppresses CAPN5 in cell lines. Quantitative PCR and immunoblot results for HEK293T-CAPN5-p.R243L (A-C) and SH-SY5Y
(D-F) show knockdown effect of shRNA transfection. A, D. CAPN5 mRNA levels relative to GAPDH (HEK293T-CAPN5-p.R243L) or β-actin (SH-SY5Y)
mRNA after transfection with each shRNA vectors as shown by percent knockdown of the respective vectors compared to the negative control
vector. Quantitative PCR data are from average of three independent experiments. B, E. Immunoblots of transfected cell lysates show calpain-5,
with GAPDH immunostaining as the loading control. C, F. Immunoblot band densities depict the average of three independent experiments. Bar
graphs were represented as a mean ± SEM.
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the inflammatory neuronal degeneration in ADNIV and
further supports a similar gene silencing strategy to res-
cue the ADNIV phenotype. ADNIV symptoms do not
begin for nearly two decades [1], so there is ample op-
portunity to intervene before the disease becomes se-
vere. The slow progression of disease also suggests that
even partial inhibition of calpain-5 could delay the dis-
ease enough to have an impact on vision, especially in
combination with other therapies [5]. Our recent devel-
opment of an ADNIV mouse model provides a preclin-
ical model to test CAPN5 RNA inhibition in vivo [6].
The eye is an optimal organ for gene therapy because it
is compartmentalized, which enhances precise gene deliv-
ery and reduces systemic dissemination that might trigger
immune responses [18]. The compartmentalization of the
eye also ensures that resident cells can be transduced
effectively with low doses of a therapeutic agent. The
numerous non-invasive imaging methods allows easy
monitoring of treatment and unwanted side effects of
gene therapy [18]. RNAi-based gene therapy may belimited by the difficulty in ensuring efficient delivery
and limiting off-target effects. Some of these setbacks
have been addressed by the use of recombinant adeno-
associated viruses (rAAVs) as an efficient vehicle to de-
liver shRNA to specific cells or tissues and the use of
tissue-specific promoters ensure that only target tis-
sues with specific promoters are able to stably express
the therapeutic gene products at effective levels long
term [19,20]. Due to these attributes, experiments and
trials employing RNAi-based gene therapy are cur-
rently underway for treatment of hereditary ophthal-
mic pathologies such as retinitis pigmentosa and age-
related macula degeneration [11,21,22]. Clinical trials
for therapy are in the planning stages for primary open
angle glaucoma [23]. If gene silencing is effective in an
ADNIV animal or cell models, a clinical trial with
ADNIV patients is feasible.
Conclusion
Short Hairpin RNA interference is an effective method
for reducing CAPN5 gene expression and may address
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blindness.
Methods
Cell culture, reagents and antibodies
Human embryonic kidney 293 T (HEK293T) and differ-
entiated human neuroblastoma SH-SY5Y cells were pur-
chased from the American Type Culture Collection
(ATCC; Manassas, VA). Cells were maintained in 90 mm
non-pyrogenic tissue culture dishes with 15 mL growth
medium at 37°C in a humidified atmosphere with 95%
air and 5% CO2. Heat-inactivated fetal bovine serum
(FBS), penicillin-streptomycin antibiotic, Dulbecco’s
Modified Eagle Medium (DMEM) containing 4500 mg/L
D-glucose and L-glutamine, without sodium pyruvate,
OptiMEM reduced serum medium and RPMI-1640
medium, both containing L-Glutamine, were all pur-
chased from Gibco (Grand Island, NY). Mouse mono-
clonal anti-GAPDH antibody (6C5), goat anti rabbit
secondary antibody and goat anti mouse secondary anti-
body were purchased from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA); rabbit polyclonal anti-calpain-5
antibody was purchased from GeneTex (Irvine, CA);
rabbit anti-myc tag antibody was purchased from Abcam
(Cambridge, MA).
HEK293T adherent cells were grown in DMEM
medium supplemented with 10% FBS, penicillin (100 U/
mL) and streptomycin (100 μg/mL) (complete DMEM
medium). The HEK293T cells were transformed into
cells that stably express a disease mutant of calpain-5 (p.
R243L). SH-SY5Y adherent cells were cultured in a 1:1
mix of RPMI 1640 and F-12 media containing 10% FBS,
penicillin (100 U/mL) and streptomycin (100 μg/mL).
Short hairpin RNA plasmids
Four unique short hairpin RNA (shRNA) sequences that
target human CAPN5 and one nontargeting sequence
(negative control) were purchased from Qiagen (Catalog#
KM40517; Frederick, MD). Each plasmid vector
expressed a shRNA under the control of a U1 pro-
moter and contained a green fluorescent protein (GFP)
reporter gene. The shRNA nucleotide sequences were:
clone one: 5’ - GTACAATGTGAAAGGCATCTT - 3’;
clone two: 5’ - CAACCACAAGGACACCTTCTT - 3’;
clone three: 5’ - GACTTCACGGGTGGTGTTTCT -
3’; clone four: 5’ - GTCAGAGAAGTTGGTGTTTCT -
3’; negative control: 5’ - GGAATCTCA TTCGATGCA
TAC - 3’.
Stable cell line creation
HEK293T cells were co-transfected with a pUS2 vector
that encodes the puromycin-resistant gene and myc-
tagged CAPN5 wild type (WT) or p.R243L (disease-al-
lele) in pCMV6 entry vector (Origene Technologies Inc.;Rockville, MD). The pUS2 vector was modified from
pCS2 entry vector by replacing the CMV promoter with
UbC promoter. In wells of separate 12-well plates,
HEK293T cells at 70% confluence in 600 μL complete
culture medium were co-transfected with 900 ng of
CAPN5 and 100 ng of puromycin plasmids using the
lipid reagent Turbofectin (OriGene Technologies, Inc.;
Rockville, MD) per manufacturers’ recommendation.
After 24-hours incubation at 37°C, the cells were trypsi-
nized and resuspended in 1 mL selection medium (com-
prising of DMEM with 10% FBS, 1% L-glutamine,
penicillin (100 U/mL), streptomycin (100 μg/mL) and
1.5 ug/mL puromycin). Briefly, 500 μL of the cell sus-
pension was added into 1.5 mL of fresh selection media
per well in new 12-well plate and incubated for 24 hours.
The transfected cells were trypsinized, serially diluted
and re-plated in separate 10 cm dishes with 10 mL selec-
tion media. The cell cultures were maintained for 12–14
days until the colonies attained diameters between 2–
4 mm. Finally, sterile forceps and cloning rings dipped
in silicone grease were used to select twenty-four dis-
tinct colonies by trypsinization, followed by incubation
at 37°C for 15 minutes, and then resuspended in 300 μL
of selection medium. The cells of each colony were cul-
tured in a new 24-well plate containing 700 μL selection
medium per well. Once the cells in each well attained 50-
70% confluence, they were seeded and cultured in a new
24-well plate for screening and also in four 6-well plates for
maintenance. The cells were screened for calpain-5 using
immunoblot. Cells were lysed on ice for 10 minutes with
HEPES buffer [50 mM HEPES (pH 7.0), 150 mM NaCl,
2 mM EGTA, 2 mM MgCl2, 1% Triton X-100, protease in-
hibitor cocktail (Roche; Indianapolis, IN)]. Twenty-two cell
lysates were collected after centrifugation at 20,000xg for
10 minutes. Equal amounts of protein were blotted and
probed with HRP-conjugated rabbit polyclonal antibody to
Myc tag (1:5000), mouse monoclonal anti GAPDH (1:400),
and secondary goat anti rabbit IgG (1:5000).
Gene suppression by shRNA plasmid transfection
HEK293T-CAPN5-p.R243L cells were transfected using
Attractene Transfection Reagent (Qiagen). In each well
of 6-well plates, 5.0 × 105 HEK293T-CAPN5-p.R243L
cells were grown in 2 mL complete DMEM medium to
50 - 70% confluence. Growth medium was replaced with
2 mL of freshly prepared Opti-MEM medium containing
5% FBS, penicillin (100U/mL) and streptomycin (100 μg/
mL) (complete Opti-MEM medium). Cells were then
transfected with 3.0 μg shRNA plasmid using 4.5 μL
Attractene Reagent. At 6 hours post-transfection, growth
medium was replaced with fresh complete Opti-MEM
medium. Cells were incubated for 48 hours.
The optimization protocols (varying pulse voltage, pulse
width and pulse, as recommended by manufacturer) for
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electroporation system (Invitrogen; Carlsbad, CA) were
performed with SH-SY5Y cells. Briefly, 1.0 × 106 SH-SY5Y
cells in 100 μL resuspension buffer were electroporated
with 12.0 μg shRNA plasmids into 150 × 20 mm tissue
culture dishes containing 15 mL Opti-MEM medium con-
taining 5% FBS. After optimization, transfection of SY-
SY5Y cells were performed in triplicate for each shRNA
plasmid and incubated for 72 hours.
Lactose dehydrogenase (LDH) assay
Toxicity of CAPN5 gene suppression on transfected cells
was measured by LDH release assay (Cytotoxicity Detection
Kit, Roche Applied Science, Mannheim, Germany).
LDH activity in the culture medium indicated LDH re-
lease from cells. Culture medium was collected from
transfected cells after 48 hours incubation. For low cyto-
toxicity control, cells were cultured without plasmid
transfection. For high cytotoxicity control, cells were
treated with 1% Triton X-100 in assay medium. Culture
media from all conditions was centrifuged at 250xg to
remove cell contaminants. The background controls
were prepared by mixing transfection medium with
Attractene or electroporation buffer. An aliquot (100 μL)
of the supernatants and the background control medium
were collected into a 96-well plate and incubated with
100 μL of freshly prepared LDH assay reaction mixture.
Incubation was performed in the dark for 30 minutes at
room temperature. Absorbance was read at 490 nm using
an Infinite M200 PRO microplate reader (Tecan Systems
Inc.; San Jose, CA). Cytotoxicity was calculated using the
equation: Cytotoxicity (%) = [(test sample – low control)/
(high control ‐ low control)] × 100.
Immunoblot
Calpain-5 levels were measured by immunoblot densitom-
etry. Cells were rinsed with 1X PBS and homogenized in
RIPA extraction buffer (1% sodium deoxycholate, 0.1%
SDS, 1% Triton X-100, 10 mM Tris–HCl, pH 8.0, 0.15 M
NaCl, 0.047 M NaF and 5.0 mM EDTA) containing prote-
ase inhibitor cocktail from Roche, Indianapolis, IN. Ho-
mogenates were sonicated on ice for 10 seconds, two
times and then centrifuged at 1000xg for 10 minutes at 4°
C. Total cellular protein was measured using the modified
Lowry method (DC Protein Assay; Bio-Rad), and equal
amounts of protein were used. Samples were denatured at
85°C for 5 minutes in LDS-sample buffer with reducing
agent (Invitrogen; Carlsbad, CA), and electrophoretically
separated using 4-12% NuPAGE Bis-Tris gels. HEK293T-
R243L proteins were transferred onto PVDF membranes
while SH- SY5Y proteins were transferred onto nitrocellu-
lose membrane. Membranes were blocked at 4°C with
5.0% non-fat dry milk in 1x TBS 0.1% tween-20. The pro-
teins were immunostained with rabbit polyclonal antibodyto calpain-5 (GeneTex; 1:1000) and mouse monoclonal
antibody to GAPDH (Santa Cruz; 1:400). Goat anti-rabbit-
HRP and goat anti-mouse-HRP antibodies (both were
used at 1:10,000 dilution ratios) were used as the second-
ary antibody. The immunoreactive bands were detected
with Supersignal West Dura Extended Duration Substrate
(Thermo Scientific; Rockford, IL). Visualization and quan-
tification of band intensities were performed with MYECL
imager and software (Thermo Scientific). We quantified
Calpain-5 expression in three independent experiments by
normalizing the calpain-5 to GAPDH and calculating the
mean expression in experimental groups (shRNA clones)
relative to the control group (negative control shRNA).Quantitative real time PCR (qPCR)
CAPN5 mRNA levels were measured by qPCR. RNA
was isolated from the cells using Qiagen RNeasy mini
kit. cDNA was prepared from 1 μg of total RNA using
High Capacity cDNA Reverse Transcription kit with
RNAse Inhibitor (Applied Biosystems Inc., Foster City,
CA). Total RNA and cDNA concentrations were mea-
sured at 260 and 280 nm using Nanodrop 2000c spec-
trophotometer (Thermo Scientific). Quantitative PCR
was performed with 100 ng of first-strand cDNA in
25 μL reaction mix using Power SYBR Green PCR Mas-





ward, 5’-ACCCTGAAGTACCCCATTG-3’; reverse, 5’-
TACGACCAGAGGCATACAG-3’. Data were normal-
ized to GAPDH mRNA for HEK293T-R243L cells and
Beta actin mRNA levels for SH-SY5Y cells. The qPCR
cycles were: 95°C for 10 min; (95°C for15 s; 60°C for
1 min) × 40 cycles. Comparative threshold cycle (Ct)
method was used to measure relative gene expression in
response to shRNA plasmid treatments. All data ana-
lyses were conducted using Prism 6.0 software (Graph-
Pad; La Jolla, CA).
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